ENLIVEN THERAPEUTICS, INC. (ELVN) Operating cash flow 2019–2025
ENLIVEN THERAPEUTICS, INC. (ELVN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$70.3MFY2025 · since FY2019: -$21.9M → -$70.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$70.3M | +3.9% |
| FY2024 | -$73.2M | -19.5% |
| FY2023 | -$61.3M | -91.0% |
| FY2022 | -$32.1M | +31.4% |
| FY2021 | -$46.8M | -25.1% |
| FY2020 | -$37.4M | -70.9% |
| FY2019 | -$21.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELVN financial trends
ELVN RevenueELVN Net incomeELVN Net marginELVN Gross profitELVN Gross marginELVN Operating incomeELVN Operating marginELVN Free cash flowELVN Capital expendituresELVN Return on equityELVN Stock buybacksELVN Dividends paidELVN Total assetsELVN Total liabilitiesELVN Shareholders’ equityELVN overview →